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To establish a productive infection, HIV-1 must counteract cellular innate immune mechanisms and redirect
cellular processes toward viral replication. Recent studies have discovered that HIV-1 and other primate im-
munodeficiency viruses subvert cell cycle regulatory mechanisms to achieve these ends. The viral Vpr and
Vpx proteins target cell cycle controls to counter innate immunity. The cell-cycle-related protein Cyclin L2
is also utilized to counter innate immunity. The viral Tat protein utilizes Cyclin T1 to activate proviral transcrip-
tion, and regulation of Cyclin T1 levels in CD4+ T cells has important consequences for viral replication and
latency. This review will summarize this emerging evidence that primate immunodeficiency viruses subvert
cell cycle regulatory mechanisms to enhance replication.CD4+ T lymphocytes and myeloid cells—macrophages and
dendritic cells—are the two major cell types infected in vivo
by HIV-1, HIV-2, and other primate immunodeficiency viruses.
To successfully replicate in these cells, the viruses must over-
come the antiviral action of multiple proteins of the innate
immune system. The importance of escaping innate immunity
is clear, as despite having relatively small genomes of 10,000
nucleotides, primate immunodeficiency viruses encode several
proteins that act to counter innate immunity—Nef, Vpr, Vpu,
and Vpx.
While all lineages of primate lentiviruses encode Vpr, the
HIV-2/SIV sooty mangabey (SIVsmm) and SIV/red-capped
mangabey/mandrill (rcm/mnd2) lineages also encode the pa-
ralog Vpx. Early genetic studies demonstrated that both Vpr
and Vpx are dispensable for viral replication in vitro, but the
proteins play important roles in vivo in experimental infection
of macaques. Deletion of either the vpr or vpx gene attenuated
SIVmac replication in rhesus macaques, although the infected
animals eventually progressed to AIDS (Gibbs et al., 1995).
Interestingly, animals infected with the vpx mutant had lower
viral burdens and slower CD4+ T cell decline than animals inoc-
ulated with the vprmutant. Deletion of both vpr and vpx severely
attenuated the virus. Furthermore, studies of SIVsmm and SIV
macaca nemestrina (mne) in pigtailed macaques demonstrated
that deletion of vpx compromised mucosal transmission and
disease (Belshan et al., 2012; Hirsch et al., 1998). Although
studies have consistently demonstrated an effect of Vpx on
macrophage tropism of SIV in vitro, deletion of vpx also appears
to severely attenuate the spread of virus through the CD4+ T cell
population in vivo (Belshan et al., 2012) Thus, for SIVs that
encode both vpr and vpx (SIVsmm and SIVrcm/mnd2), Vpx
may be more critical than Vpr for replication in Old World mon-
keys, and it likely makes important contributions to viral replica-
tion in both macrophages and CD4+ T cells.
Cell-Cycle-Regulated CDKs Overcome SAMHD1
The importance of Vpx was determined in quiescent CD4+T
cells, monocytes, and dendritic cells. These are non-dividing
cells that are generally not permissive for HIV-1 infection, but736 Cell Host & Microbe 17, June 10, 2015 ª2015 Elsevier Inc.infection of these cells could be enhanced by incorporation of
the HIV-2 Vpx protein into HIV-1 virions (Goujon et al., 2008).
Early work indicated that Vpx functions in this experimental sys-
tem to overcome a restriction factor in non-dividing cells that
acts early at a post-entry stage to inhibit reverse transcription
(Fletcher et al., 1996). The analysis of mutant Vpx proteins estab-
lished a correlation between the ability of Vpx to enhance reverse
transcription and to associate with a ubiquitin E3 ligase complex
composed of DCAF1-DDB1-CUL4A-RBX1 (Le Rouzic et al.,
2007; Srivastava et al., 2008). Thus, it was believed that Vpx
enhances reverse transcription through proteasome-mediated
proteolysis of a restriction factor. Using mass spectrometry
technology to identify cellular proteins that co-immunoprecipi-
tated with wild-type but not with a mutant Vpx unable to asso-
ciate with DCAF1, SAMHD1 was identified as this key restriction
factor in non-dividing cells (Hrecka et al., 2011; Laguette et al.,
2011).
Prior to its discovery as a target of Vpx, SAMHD1was linked to
the immune system, as mutations in SAMHD1 were known to
cause Aicardi-Goutieres syndrome, a condition involving chronic
inflammation and reminiscent of persistent viral infections
(Rice et al., 2009). SAMHD1 is a phosphohydrolase that cleaves
dNTPs into deoxynucleotides and inorganic triphosphates.
In quiescent CD4+ T cells, monocytes, and dendritic cells,
SAMHD1 activity depletes the dNTP pool required for efficient
HIV-1 reverse transcription. SAMHD1 also possesses a 30-to-50
exonuclease activity that degrades single-stranded RNA and
single strand DNA overhangs, and this activity has been associ-
ated with inhibition of HIV-1 reverse transcription. Vpx over-
comes the antiviral activity of SAMHD1 by loading it onto the
DCAF1-DDB1-CUL4A-RBX1 E3 ubiquitin ligase complex, result-
ing in efficient proteasome-mediated degradation of SAMHD1
(Figure 1).
With the discovery of SAMHD1 as a potent HIV-1 restriction
factor in quiescent CD4+ T cells, monocytes, and dendritic cells,
a conundrum arose as SAMHD1 is expressed at high levels in
activated CD4+ T cells and monocytic cell lines—proliferating
cells that support robust HIV-1 replication. Clearly, the expres-
sion level of SAMHD1 is not sufficient to inhibit HIV-1 replication.
Figure 1. Inhibition of SAMHD1 Antiviral
Activity
SAMHD1 possesses phosphohydrolase and
exonuclease activities that have been shown to
inhibit retroviral cDNA synthesis (top panel). In
activated CD4+ T cells and proliferating cell lines,
CDKs inactivate SAMHD1 through phosphoryla-
tion of T592 (left bottom panel). In resting CD4+
T cells, monocytes, and dendritic cells, the viral
Vpx protein functions to degrade SAMHD1
through loading it onto the DCAF1/DDB1/CUL4A/
RBX1 E3 ubiquitin complex (bottommiddle panel).
In macrophages, the cellular Cyclin L2 protein
functions to degrade SAMHD1 through loading it
onto the E3 ubiquitin complex (bottom right panel).
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cyclin-dependent kinases (CDKs) activated during the cell cycle
of proliferating cells can inactivate SAMHD1 through phosphor-
ylation of threonine 592 (T592) (White et al., 2013; Cribier et al.,
2013). The mechanism whereby this phosphorylation inactivates
SAMDH1 is presently unclear, as there are conflicting reports on
the effects on phosphohydrolase activity (White et al., 2013; Yan
et al., 2015; Ruiz et al., 2015). Additional studies are required to
clarify to what extent T592 phosphorylation inhibits SAMHD1
phosphohydrolase and nuclease activity and the relative impor-
tance of each activity for anti-HIV-1 activity.
To date, three CDKs—CDK1, CDK2, and CDK6—have been
reported to phosphorylate SAMHD1 T592 in proliferating cells
(Pauls et al., 2014; White et al., 2013; Cribier et al., 2013; St Ge-
lais et al., 2014). Because these CDKs are generally not active in
non-proliferating cells, SAMHD1 lacks T592 phosphorylation
and is able to function as a restriction factor to inhibit HIV-1
reverse transcription in these cells. In proliferating cells, cell-cy-
cle-regulated CDKs are activated and HIV-1 can take advantage
of this regulation to evade SAMHD1 and achieve robust replica-
tion (Figure 1).
Evolutionary analyses have shown that SAMHD1 antagonism
is a highly conserved activity of primate lentiviruses infecting
some Old World monkeys but not hominoids (Lim et al., 2012).
Vpx and some Vpr proteins from SIVs are able to degrade the
SAMHD1 protein of their natural hosts, and the ability of SIVs
to degrade SAMHD1 preceded the evolution of the vpx gene,
which presumably occurred through recombination/duplication
of the vpr gene and subsequent divergence of one allele into
vpx. Moreover, Vpr/Vpx-mediated antagonism resulted in
strong positive selection of SAMHD1 in the primate subfamily
Cercopithecinae, but not hominoids or New World monkeys,
indicating the importance of targeting SAMHD1 for infection
of many Old World monkeys. Vpx, and the ability to inhibit
SAMHD1, was deleted during the evolution of SIVcpz from
two SIV lineages of Old World monkeys, and the absence ofCell Host & MicrobeSAMHD1 degrading activity was main-
tained with adaptation of HIV-1 to hu-
mans (Etienne et al., 2013). However,
this phenotype may not be a prerequisite
for infection of a species, as in contrast to
HIV-1, HIV-2 does degrade SAMHD1 in
human cells. Furthermore, mandrills are
also infected by SIVs that encode eitheronly Vpr (SIVmnd1) or both Vpr and Vpx (SIVmnd2). Thus, the
lack of SAMHD1 antagonism by certain primate lentiviruses
may be the consequence of the evolution of unique replication
mechanisms that obviate a requirement to inhibit SAMHD1.
Cyclins Exploited by HIV-1
The term ‘‘Cyclin’’ was first given to a protein detected in fertil-
ized sea urchin eggs that was degraded at certain points in the
cell cycle (Evans et al., 1983). This degradation was subse-
quently shown to occur via proteasome-mediated proteolysis,
and approximately 30 Cyclin proteins are now known to be en-
coded in the human genome. Some Cyclins are key regulators
of the cell cycle through their binding to and activation of
CDKs, followed by the subsequent proteolysis of the Cyclin at
define points in the cell cycle. Other Cyclin-CDK pairs regulate
cellular processes that are not directly related to cell cycle
control, such as stimulation of RNA Polymerase II (RNAP II) tran-
scriptional elongation by Cyclin T1/CDK9 (discussed below).
Cyclin L2 Degrades SAMHD1 in Macrophages
Efficient replication of HIV-2 in macrophages requires the inter-
action of Vpxwith DCAF1, and a yeast two-hybrid system screen
was therefore carried out to identify DCAF1-associated proteins
(Kyei et al., 2015). Cyclin L2 was identified in this screen, and this
Cyclin is involved in cell cycle regulation and pre-mRNA splicing,
although the mechanisms whereby it is involved in these pro-
cesses are poorly understood. Cyclin L2 forms a complex with
DCAF1 and SAMHD1, resulting in the proteasome-mediated
degradation of SAMHD1. siRNA knock-down of cyclin L2 re-
duces HIV-1 replication in macrophages but not proliferating
cells (where SAMHD1 is inactivated by CDKs). In macrophages,
therefore, Cyclin L2 inactivates SAMHD1 through proteolysis,
thereby enhancing HIV-1 replication in this cell type (Figure 1).
Cyclin T1 Affects HIV-1 Latency in CD4+ T Cells
Cyclin T1 has long been known to be targeted by HIV-1. Cyclin
T1 is the regulatory subunit of CDK9, and the Cyclin T1/CDK9
heterodimer is the catalytic core of a general RNAP II elongation17, June 10, 2015 ª2015 Elsevier Inc. 737
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of the retroviral trans-activator protein Tat, RNAP II initiates tran-
scription from the viral 50 LTR sequences, but elongation is
restricted by the action of two cellular factors termed DSIF and
NELF. To stimulate elongation, Tat binds directly to Cyclin T1
and CDK9 in P-TEFb, and this complex binds to the viral TAR
RNA element that forms at the 50 end of viral transcripts. CDK9
is then positioned to phosphorylate both the carboxyl terminal
domain of RNA Polymerase II and the negative factors that
restrict elongation, leading to a potent stimulation of elongation.
Regulation of Cyclin T1 in CD4+ T lymphocytes is of consider-
able significance for HIV-1 replication and latency. HIV-infected
individuals treated with suppressive antiviral therapy contain a
population of quiescent memory CD4+ T cells with transcription-
ally silent or latent HIV-1 proviruses. Upon cessation of anti-viral
drugs, viruses in this latent reservoir reactivate and rekindle
infection, thereby precluding a cure of infection by current anti-
viral drugs. Tat activity is limiting for productive transcription of
latent proviruses in CD4+ T cells from these infected individuals
(Lassen et al., 2004), and this is due in part to limiting levels of
Cyclin T1. Cyclin T1 protein levels are low in resting CD4+
T cells due to repression by several miRNAs: miR-27b, miR-
29b, miR-150, andmiR-223 (Chiang et al., 2012). T cell activation
reduces the level of these miRNAs relative to Cyclin T1 mRNA,
leading to a strong increase in Cyclin T1 protein expression.
Unlike Cyclin T1, CDK9 protein levels are high in resting CD4+
T cells. However, CDK9 catalytic activity is quite low in resting
cells due to the lack of phosphorylation of threonine 186 in the
CDK9 T-loop—phosphorylation of the T-loop allows access of
substrates to the enzyme’s catalytic core. The phosphatase
PPM1A is involved in dephosphorylation of the T-loop in resting
CD4+ T cells (Budhiraja et al., 2012). Upon T cell activation, there
is a rapid phosphorylation of the CDK9 T-loop leading to active
P-TEFb (Ramakrishnan et al., 2009), and CDK7 has been
identified as the kinase that phosphorylates the CDK9 T-loop
(Larochelle et al., 2012).
Although Cyclin T1 has not been shown to be directly involved
in cell cycle regulation, it is degraded by proteasome-mediated
proteolysis when activated CD4+ T cells return to quiescence,
and this appears to be important in the establishment of latent
infection (Budhiraja et al., 2013). A PEST sequence, which
is thought to initiate degradation, at the carboxyl terminus of
Cyclin T1 is likely to be a signal for proteolysis in cells returning
to quiescence. Upregulation of Cyclin T1 following activation
of quiescent CD4+ cells is required for reactivation of latent
HIV-1, further indicating that Cyclin T1 is a limiting factor for
HIV-1 replication in quiescent CD4+ T cells (Tyagi et al., 2010).
Vpr Cell Cycle Arrest and SLX4 Complex
In 1995, several groups reported that the HIV-1 Vpr protein
induces cell cycle arrest at the G2/M transition (reviewed in
Andersen and Planelles, 2005). Subsequent studies found that
the cell cycle arrest involves the DNA damage checkpoint
network and activation of the ATR and Chk1 kinases (Andersen
and Planelles, 2005). However, the importance of cell cycle ar-
rest to HIV-1 replication proved remarkably difficult to elucidate.
Critical data were obtained when Vpr was found to associate
with a DCAF1-DDB1-Cul4 E3 ligase complex, and analyses of
mutant Vpr proteins indicated that this association is required738 Cell Host & Microbe 17, June 10, 2015 ª2015 Elsevier Inc.for cell cycle arrest (Belzile et al., 2007; DeHart et al., 2007;
Hrecka et al., 2007; Le Rouzic et al., 2007; Schro¨felbauer et al.,
2007). These findings let to the expectation that Vpr cell cycle
arrest is the result of degradation of a key cellular protein whose
downregulation induced cell cycle arrest.
In a recent comprehensive study, Vpr was found to interact
with the SLX4 scaffold protein and the structure-specific endo-
nucleases (SSEs) MUS81-EME1 and ERCC1-ERCC4 (Laguette
et al., 2014). The complexes formed between SLX4 and these
SSEs, termed SLX4coms, resolve secondary DNA structures
generated during DNA repair and recombination such as Holli-
day junctions. SLX4coms are under strict cell cycle regulation
as their inappropriate activation can result in chromosome insta-
bility. Biochemical experiments by Laguette and colleagues
showed that Vpr interacts directly with the carboxyl terminus of
SLX4, and the viral protein is present in a distinct SLX4com
consisting of DCAF1, MUS81-EME1, and SLX4. The interaction
between SLX4com and Vpr is quite specific, as the related
HIV-2 Vpx protein does not associate with the SLX4com. The
endonuclease activity of the MUS8-EME1 SSE is stimulated by
phosphorylation of EME1 by Polo-Like Kinase 1 (PLK1), and
Laguette and colleagues found that Vpr and DCAF1 recruit
active PLK1 into the SLX4com (Figure 2). Additional biochemical
experiments showed that association of Vpr and DCAF1 with the
SLX4com stimulates endonuclease activity in vitro, and the
association in vivo results in the accumulation of punctate struc-
tures termed FANCD2 foci, which are markers of damaged DNA
due to deficient cleavage of replication intermediates.
Substantial data indicate that inappropriate activation of
the SLX4com by Vpr induces G2/M arrest. Formation of the
Vpr/SLX4com precedes cell cycle arrest, and siRNA depletion
of SLX4, EME1, or MUS81 reduces Vpr-induced G2/M arrest
(Laguette et al., 2014). Mutant Vpr proteins unable to associate
with the SLX4com do not induce cell cycle arrest. An analysis
of Vpr proteins from a number of SIVs identified a correlation in
human cells between the ability of SIV Vpr proteins to associate
with SLX4 and induce the G2/M arrest (Berger et al., 2015). For-
mation of the Vpr-SLX4com leads to ubiquitination and degrada-
tion of the MUS81 subunit of the complex (Laguette et al., 2014;
DePaula-Silva et al., 2015). However, degradation of MUS81 can
be rather modest, and as stated above, MUS81 siRNA deple-
tions reduce rather than promote Vpr-mediated cell cycle arrest.
Vpr Activation of SLX4com Prevents Interferon
Induction
How does Vpr activation of the SLX4com benefit HIV-1 replica-
tion? A major benefit is likely to be impairment of the host cell’s
ability to sense infection and induce IFN. SLX4 belongs to the
Fanconi Anemia (FA) family of proteins in which mutations result
in increased susceptibility to cancer and bone marrow failure, as
well as abnormal production of IFN and proinflammatory cyto-
kines. Vpr activation of the SLX4com appears to allow the endo-
nuclease to degrade HIV-1 reverse transcripts and help the virus
to evade detection by the innate immune system (Figure 2).
SiRNA depletion of MUS81, DCAF1, or SLX4 leads to induction
of IFN following HIV-1 infection, while infection with a Vpr-
deleted virus induces IFN (Laguette et al., 2014). Furthermore,
SLX4 co-immunoprecipitated with HIV-1 reverse transcription
products, and this was largely dependent upon Vpr, presumably
Figure 2. Vpr Activation of SLX4com and
Cell Cycle Arrest
The viral Vpr protein binds to the SLX4complex
that contains the MUS81/EME1 SSE. Vpr also re-
cruits the kinase PLK1, which phosphorylates
EME1 to stimulate endonuclease activity. The
nuclease activity of the SLX4complex degrades
viral cDNA, thereby preventing detection of infec-
tion by the innate immune system. Inappropriate
activation of MUS81/EME1 nuclease activity by
Vpr results in G2/M cell cycle arrest. Vpr also re-
cruits the DCAF1/DDB1/CUL4A/RBX1 E3 ubiq-
uitin complex to the SLX4complex, leading to
degradation of MUS81.
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and the subsequent degradation of cDNA.
It has been estimated that up to 90% of HIV-1 reverse tran-
scripts do not integrate (Suspe`ne and Meyerhans, 2012), and
these viral products are potential signals of infection that can
be recognized by the innate immune system. The exonucleases
TREX1 and RNASEH2 have been implicated in degrading exces-
sive HIV-1 reverse transcripts, thereby preventing IFN induction
(Yan et al., 2010; Genovesio et al., 2011). Given the recent find-
ings by Laguette and colleagues, Vpr activation of the endonu-
clease activity of SLX4com also contributes to the degradation
of viral transcripts. The finding that multiple cellular nucleases
degrade HIV transcripts suggests that reverse transcription pro-
duces a large excess of transcripts over that needed for replica-
tion. Reverse transcription of the HIV-1 genome is clearly an
effective but apparently inelegant step in the viral replication
strategy—the virus synthesizes far too much viral cDNA and
must utilize cellular nucleases to degrade the excess to avoid
detection by the innate immune system.
Future Perspectives
The recent findings described above have led to the appreciation
that HIV-1 and other primate immunodeficiency viruses subvert
cell cycle regulatory mechanisms as part of their replication
strategy, especially to counter innate immune mechanisms.
A number of intriguing questions have been raised by these
findings, and there will surely be rapid progress in this area.
Does SAMHD1 function as a restriction factor for other viruses,
especially other families of retroviruses and DNA viruses? If so,
what countermeasures do these viruses utilize to overcome
SAMHD1? The Vpx protein is involved in spread of SIV through
the population of CD4+ T cells in vivo (Belshan et al., 2012).
Does Vpx enhance viral replication in CD4+ T cells in vivo through
mechanisms that do not involve SAMHD1? Furthermore, previ-
ous studies found that in the early stages of human infection,
high levels of HIV-1 replication could be observed in restingCell Host & MicrobeCD4+ T cells (Zhang et al., 1999). As
SAMHD1 activity should be high in these
resting cells, what mechanisms allow
HIV-1 replication in resting CD4+ T cells?
What are the molecular events by which
activation of the SLX4com by Vpr leads
to G2/M arrest, and will elucidation of
these events provide general insight into
the cell cycle? In addition to associatingwith the MUS81/EME1 endonuclease in the SLX4com, Vpr
also associates with the structure-specific ERCC1/ERCC4
endonuclease (Laguette et al., 2014). Does this endonuclease
also degrade viral cDNA, or might ERCC1/ERCC4 and MUS91/
EME1 have separate functions that contribute to HIV-1 replica-
tion? Finally, mutations in SAMHD1 are associated with
Aicardi-Goutieres syndrome, a chronic inflammatory disease,
and mutations in SLX4 are associated with FA, a disease
involved in susceptibility to cancer and abnormal production of
proinflammatory cytokines. Future studies of the dysregulation
of these proteins by the primate immunodeficiency viruses are
likely to provide insight into these and related human genetic
diseases.
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